Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Medicilon Assists | Cullgen's class 1 new drug TRK degrader CG001419 was approved for clinical use

Page View:

On August 8, 2022, Cullgen Inc announced the approval of the IND application for a TRK degrader (CG001419) for the treatment of advanced solid tumors.  CG001419 is the world's first in class TRK (neurotrophic factor receptor tyrosine kinase) protein degrader.


Shanghai Medicilon Inc., as the collaborative CRO of Cullgen, relies on the PROTAC technology platform to provide comprehensive preclinical research services that comply with both China and US GLP standards for the R&D of CG001419 (including pharmacokinetic research and safety evaluation) and helped CG001419 to successfully get approved.
Relevant newsRelevant news